LEPU BIO-B (Lepu Biopharma Co., Ltd.) has distributed its 2025 annual general-meeting (AGM) circular, setting out key proposals for shareholder approval on 19 May 2026 in Beijing.

Key AGM Items 1. 2025 Performance Documents • Board and Supervisory reports, full annual report and financial statements for FY-2025 will be tabled. • The company recorded “no profit available for distribution”; accordingly, the 2025 profit-distribution plan recommends neither a cash dividend nor a capital-reserve conversion.

2. 2026 Financial Budget • Resources will be directed to product commercialisation, clinical trials and daily operations. No quantitative budget targets were disclosed in the circular.

3. Capital-Market Actions • General mandate: the Board seeks authority to issue up to 360.89 million additional H-shares—20% of the existing 1.80 billion share base—during the mandate period. • Re-appointment of Ernst & Young as auditor for FY-2026 at an estimated audit fee of RMB2.90 million.

4. Governance Updates • Proposed appointment of Ms Fan Xinyu as supervisor with an annual remuneration of RMB0.15 million, succeeding the retiring Mr Yang Ming. • Proposal to move the company’s registered address to Block 4, No. 651 Lianheng Road, Minhang District, Shanghai. • Corresponding amendments to the Articles of Association reflect the new address.

Procedural Details • The H-share register will be closed from 14 May to 19 May 2026 for AGM eligibility. • Shareholders may vote by proxy; all resolutions will be decided by poll.

The Board recommends approval of all proposals, citing alignment with the company’s operational needs and strategic objectives.